

Designing for Change



Institute for Healthcare Quality,
Safety and Efficiency

SCHOOL OF MEDICINE

UNIVERSITY OF COLORADO **ANSCHUTZ MEDICAL CAMPUS**

Financial Disclosures: NONE



Submitted for Publication (or will be very soon)



Reproduced with permission (AND terminology)



Agenda

1 Choice Architecture + Nudge

2 Design Thinking

----- Break -----

3 User-Centered Design

4 Pre-Mortem Analysis



Learning Objectives

- 1 Explain the hierarchy of intervention effectiveness.
- 2 Define choice architecture.
- 3 Identify behavioral nudges.
- 4 Explain Design Thinking.
- 5 Recognize the importance of user-empathy in good design.
- 6 Describe the process of user-centered design.
- 7 Explain the purpose and process of a pre-mortem analysis.





Session	Session Overview
Quality Improvement & Change Management	<ul style="list-style-type: none">• Basics of Quality Improvement• Step-wise, practical implementation guide• Change Management framework overview for driving change
Applied Patient Safety	<ul style="list-style-type: none">• Guide the development and participation in a systems-based case review conference.
Designing for Change	<ul style="list-style-type: none">• Understanding the problem and the people involved• Design thinking and choice architecture• User-centered design methodology• Pre-mortem analysis to identify the right solutions for the right problem
Acquiring Data to Drive Change	<ul style="list-style-type: none">• Data sources to track improvement• Data analysis and organization• Data visualization
Spreading Change Locally and Nationally	<ul style="list-style-type: none">• Diffusion of innovation framework• QI vs. research• Strategies for dissemination and publication• Grant opportunities
Coaching and Teaching Quality Improvement	<ul style="list-style-type: none">• How to coach QI teams• Identifying and troubleshooting common QI missteps





BestPractice Advisory - Roo, Koda

Attention (1)



! Hyperlipidemia (BPA # 89568)

Your patient may have hyperlipidemia based on an encounter or problem list diagnosis.

RECOMMENDATION: Consider starting a statin medication.

This is a best practice at our institution.

[↗ Open hyperlipidemia treatment pathway](#)

Dismiss





(Humans are) Lazy, Forgetful Creatures of Habit

Being a lazy, forgetful creature of habit is completely rational. We only have so much energy and attention, and we have ever increasing demands on it. Why should you do anything that requires more work? Why should you go out of your way? Or commit something to memory, when Google will remember it for you?

Erika Hall


Author of *Conversational Design* and *Just Enough Research*

<https://medium.com/research-things/lazy-forgetful-creatures-of-habit-2758e6976d4>

<https://unsplash.com/photos/GTXvpZ2eTdA>



THE FORGETTING CURVE




Ebbinghaus, Hermann (1913). *Memory: A Contribution to Experimental Psychology*. Translated by Ruger, Henry; Bussenius, Clara. New York city, Teachers college, Columbia university.

<https://elearningindustry.com/forgetting-curve-combat>



The Hierarchy of Intervention Effectiveness



WHO Surgical Safety Checklist
(adapted for England and Wales)


National Patient Safety Agency
National Reporting and Learning Service

SIGN IN (To be read out loud)	TIME OUT (To be read out loud)	SIGN OUT (To be read out loud)
<p>Identify patient and procedure</p> <p>Has the patient confirmed his/her identity, the procedure and consent?</p> <p><input type="checkbox"/> Yes</p> <p><input type="checkbox"/> No</p> <p>Is the surgical site marked?</p> <p><input type="checkbox"/> Yes</p> <p><input type="checkbox"/> No</p> <p>Is the anaesthesia machine and medication check complete?</p> <p><input type="checkbox"/> Yes</p> <p><input type="checkbox"/> No</p> <p>When the patient has a known allergy?</p> <p><input type="checkbox"/> No</p> <p><input type="checkbox"/> Yes</p> <p>High airway/respiration risk?</p> <p><input type="checkbox"/> No</p> <p><input type="checkbox"/> Yes</p> <p>High equipment/assistance available?</p> <p><input type="checkbox"/> No</p> <p><input type="checkbox"/> Yes</p> <p>Risk of >100ml blood loss (Check to be undertaken)?</p> <p><input type="checkbox"/> No</p> <p><input type="checkbox"/> Yes, and adequate IV access/fluid planned</p>	<p>Check time of surgical intervention for anaesthetic and fluids</p> <p>Has the anaesthetic been confirmed by name and used?</p> <p><input type="checkbox"/> Yes</p> <p><input type="checkbox"/> No</p> <p>Has the anaesthetic and Registered Practitioner verified jointly?</p> <p><input type="checkbox"/> Yes</p> <p><input type="checkbox"/> No</p> <p>What procedure, site and position are planned?</p> <p>Has the anaesthetic been confirmed by name and used?</p> <p><input type="checkbox"/> Yes</p> <p><input type="checkbox"/> No</p> <p>Are there any critical or unexpected steps you need the team to know about?</p> <p>Are there any specific equipment requirements or special monitoring?</p> <p>Are there any critical or unexpected steps you need the team to know about?</p> <p>Are there any patient specific concerns?</p> <p>What is the patient's risk grade?</p> <p>What monitoring equipment and other specific levels of support are required, for example blood?</p> <p>Are there any equipment issues or concerns?</p> <p>Has the availability of the instrumentation been confirmed (including indicator results)?</p> <p>Are there any equipment issues or concerns?</p> <p>Has the surgical site infection (SSI) bundle been undertaken?</p>	<p>Check name and location of End Vessel Service (the operating room)</p> <p>Has the name of the procedure been recorded?</p> <p><input type="checkbox"/> Yes</p> <p><input type="checkbox"/> No</p> <p>Has it been confirmed that independently, study and sign-out are complete (or not applicable)?</p> <p><input type="checkbox"/> Yes</p> <p><input type="checkbox"/> No</p> <p>Has the sign-out been confirmed?</p> <p><input type="checkbox"/> Yes</p> <p><input type="checkbox"/> No</p> <p>Have any patient problems been identified that need to be addressed?</p> <p>Signatures, Anaesthetist and Registered Practitioner</p> <p><input type="checkbox"/> What are the key concerns for recovery and management of this patient?</p>

This checklist contains the core content for England and Wales




The Hierarchy of Intervention Effectiveness



What about electronic alerts?



The Hierarchy of Intervention Effectiveness



BestPractice Advisory - Roo, Koda

Attention (1)

Hyperlipidemia (BPA # 89568)

Your patient may have hyperlipidemia based on an encounter or problem list diagnosis.

RECOMMENDATION: Consider starting a statin medication.


This is a best practice at our institution.

[Open hyperlipidemia treatment pathway](#)

Dismiss



The Hierarchy of Intervention Effectiveness



CT Low Dose Chest CT For Annual Lung Cancer Screening ✓ Accept ✗ Cancel

Status: Normal Standing Future

Expected Date: Today Tomorrow 1 Week 2 Weeks 1 Month Approx.
3 Months 6 Months

Expires: 9/13/2023 1 Month 2 Months 3 Months 4 Months 6 Months 1 Year 18 Months

Priority: Routine Routine STAT

Class: Ancillary Performed Ancillary Performed Hospital Performed External

Reason for Exam: ⓘ

Lung cancer screening, < 20 pk-yr smoking history (Age >= 50y) Lung nodule, > 8mm Non-small cell lung cancer (NSCLC), monitor

Lung cancer screening, >= 20 pk-yr smoking history (Age >= 50y) Lung nodule, 6-8mm Non-small cell lung cancer (NSCLC), non-metastatic, assess treatment response

Lung nodule, < 6mm, high cancer risk Lung nodules, multiple Non-small cell lung cancer (NSCLC), recurrence

Lung nodule, < 6mm, high cancer risk, stable on prior exam Lung nodules, multiple < 6mm, stable on prior exam

Lung nodule, < 6mm, low cancer risk Non-small cell lung cancer (NSCLC), metastatic, assess treatment response

Is the patient an asymptomatic adult between 50 and 77 years old (or up to 80 yo if Medicaid patient)? Yes No

Is the patient completely free of any signs or symptoms of lung cancer? Yes No

Is this the first (baseline) CT or an annual exam? ⓘ Annual Baseline

Is the patient a current smoker or did they quit < 15 years ago? Current smoker Quit < 15 years ago

Was there a shared-decision making conversation that involved the use of one or more decision aids? Yes No

Did the conversation/aid(s) describe the benefits and harms of screening? Yes No



Did the conversation/aid(s) describe possible follow up diagnostic testing? Yes No


Did the conversation/aid(s) describe the risk of "over diagnosis"? Yes No

Did the conversation/aid(s) describe the risk of false positives? Yes No

Next Required ✓ Accept ✗ Cancel


The Hierarchy of Intervention Effectiveness





Nudge and Choice Architecture






A nudge...is any aspect of the choice architecture that **alters people's behavior in a predictable way without forbidding any options or significantly changing their economic incentives.**

To count as a mere nudge, the intervention **must be easy and cheap to avoid.** Nudges are NOT mandates. Putting fruit at eye level counts as a nudge. Banning junk food does not.

Choice architecture is the **design of different ways in which choices can be presented** to decision makers, and the impact of that presentation on decision-making.








Effective consent rates, online experiment, as a function of default.





Effective consent rates, by country. Explicit consent (opt-in, gold) and presumed consent (opt-out, blue).



Choice Architecture (Nudge): Categories

Decision structure: alter the utility of choice options through their arrangement in the decision

Decision information: increase the availability, comprehensibility, and/or personal relevance of information

Decision assistance: facilitate self-regulation



Choice Architecture (Nudge): Categories

Decision structure

- Setting a default option.
- Changing the ease of choosing certain options: either making a good option easier to choose, or a bad option harder to choose.
- Changing the saliency of certain options: either making a good option more noticeable, or a bad option less noticeable.



Choice Architecture (Nudge): Categories

Provide social reference point. Initial piece of information that people rely on strongly when making subsequent judgments and decisions.

Decision information

For example, a charity soliciting donations can tell donors that “most people donate \$20”, in order to nudge people to donate more money than they would otherwise.

Make information visible

Provide access to relevant information.



Choice Architecture (Nudge): Categories

Decision assistance


Reminding people to do something.

Change option consequences: adjusting incentives or consequences of a specific behavior.

Facilitate commitment: Encourage self or public commitment to counteract failures of self-control.



Peripherally Inserted Central Catheter (PICC)



© 2015 Terese Winslow LLC
U.S. Govt. has certain rights



Annals of Internal Medicine

The Michigan Appropriateness Guide for Intravenous Catheters (MAGIC): Results From a Multispecialty Panel Using the RAND/UCLA Appropriateness Method

Vineet Chopra, MD, MSc; Scott A. Flanders, MD; Sanjay Saint, MD, MPH; Scott C. Woller, MD; Naomi P. O'Grady, MD; Nasia Safdar, MD, PhD; Scott O. Trerotola, MD; Rajiv Saran, MD, PhD; Nancy Moureau, BSN, RN; Stephen Wiseman, PharmD; Mauro Pittiruti, MD; Elie A. Akl, MD, MPH, PhD; Agnes Y. Lee, MD, MSc; Anthony Courey, MD; Lakshmi Swaminathan, MD; Jack LeDonne, MD; Carol Becker, MHA; Sarah L. Krein, PhD, RN; and Steven J. Bernstein, MD, MPH

Project Goals

1. increase proportion of midline catheters
2. decrease lumens of PICCs



Insert PICC line by IV Team ✓ Accept ✗ Cancel

Priority: Routine

Frequency: **ONCE**

At: Today Tomorrow

Comments: Insert SmartText 100%

Type of PICC line: **PICC LINES** - Confirmation of placement, care and maintenance per Infusion Nurses Society Infusion Standards of Practice.

- Single Lumen Groshon
- Double Lumen Groshon
- Triple Lumen PICC
- PowerPICC

The Comments field contains u... artLists.

Recreation of baseline PICC order (without any guidance)

Order Sets

❗ UCH Adult Midline - PICC Placement and Care ^

Always use a midline if appropriate.

If PICC line needed, minimize number of lumens.

Multiple lumen catheters = greater risk of infection and thrombosis.

INR must be < 3.0 and platelets > 50,000.

If CKD/dialysis patient, order Hohn catheter instead.

Please call the PICC team with specific requests.

▼ General

▼ ❗ Main Indication for IV Access


- Discharging with a Line
- Short-Term IV Access (Less Than 15 Days)
- Long-Term IV Access (Greater Than 15 Days)
- Frequent Phlebotomy
- Medication(s) requiring central access (e.g. vasopressors, chemo, TPN...)



Decision Information

Intervention order-set





Decision Structure

▼ General

▼ Main Indication for IV Access

- Discharging with a Line
- Short-Term IV Access (Less Than 15 Days)
 - Is patient discharging with a line or needing access for vasopressors, chemotherapy, or TPN?
 - Yes

Your patient likely requires a PICC line based on your response to the previous question.

 - IR PICC line
 - Sign
 - No
 - Long-Term IV Access (Greater Than 15 Days)
 - Frequent Phlebotomy
 - Medication(s) requiring central access (e.g. vasopressors, chemo, TPN...)
- ▼ Central/Midline Line Approved for Use and for Blood Draws
 - Central line approved for use

Routine, UNTIL DISCONTINUED starting Today at 1912 Until Specified
PICC RN to Release, Sign & Hold
- ▼ IV access Placement and Care
 - NS Flush (Heparin Contraindicated)



Decision Information

▼ General

▼ Main Indication for IV Access

- Discharging with a Line
- Short-Term IV Access (Less Than 15 Days)
- Long-Term IV Access (Greater Than 15 Days)
- !** Frequent Phlebotomy
 - IR Midline (Consider for LESS THAN 6 days)
 - IR PICC line (Preferred for 6 days or More)
 - Medication(s) requiring central access (e.g. vasopressors, chemo, TPN...)
- ▼ Central/Midline Line Approved for Use and for Blood Draws
 - Central line approved for use

Routine, UNTIL DISCONTINUED starting Today at 1912 Until Specified
PICC RN to Release, Sign & Hold
- ▼ IV access Placement and Care
 - NS Flush (Heparin Contraindicated)

NS injection flush 10 mL
10 mL, Intra-catheter, EVERY MORNING, First Dose Tomorrow at 0600, PICC RN to Re

And

NS injection flush 10 mL

Intervention order-set (cont.)



IR PICC line ✔ Accept ✖ Cancel

Priority:

! New line or Replacement

! Desired number of lumens

! Triple Lumen PICC (Restricted)

! If patient to be discharged with PICC line, Physician/Ordering Clinic/Dept is aware of their responsibility to order patient's supplies, make arrangements for home health care and education prior to placement of PICC Line:

! Responsible provider pager number and after hours or weekend pager (if applicable):

Decision Information




Intervention PICC order

Increase midline usage as a proportion of all lines

Binomial linked mixed model with a random intercept for patient MRN.

Mixed model to account for patients who had multiple encounters with midline or PICC line procedures performed during the time frame.

The odds of having a midline were 3.1 times higher after November 19, 2017 as compared to before ($p = 0.000001$).




Bredenberg E, et al. Promoting appropriate midline catheter and PICC placement through implementation of an EHR-based clinical decision support tool: An interrupted time-series analysis. *J Hosp Med.* 2023;18(6):483-490.



Increase proportion of single lumen PICCs as a proportion of all PICCs

Significant immediate increase at intervention (p-value: 0.0184), and the post-intervention slope was significantly greater than the pre-intervention slope (p-value: 0.0203).

There was an estimated immediate one-time increase in the proportion of single lumen PICC line procedures of 5.7% at the time of the intervention.



Bredenberg E, et al. Promoting appropriate midline catheter and PICC placement through implementation of an EHR-based clinical decision support tool: An interrupted time-series analysis. *J Hosp Med.* 2023;18(6):483-490.





Red Blood Cell (pRBC) Transfusion Recommendations

pRBCs are most likely APPROPRIATE in the following clinical scenarios:

- Hgb < 7 g/dL OR Hgb < 8 with CV disease AND symptoms
- Hemodynamically unstable patient with an acute bleed
- Perioperative acute blood loss anemia with expected Hgb < 7
- Cytotoxic chemotherapy with expected Hgb < 7
- Anemia with symptoms that are intolerable without transfusion

Transfuse 1 unit at a time unless Hgb <6.0 or bleeding out



COST = ~\$700
Per Unit

50% of non-OR, non-MTP, inpatient transfusions **DID NOT** meet guidelines





Prepare Order

Original

Prepare RBCs for Transfusion (must have Type and Screen available) ✓ Accept ✗ Cancel

Priority:

Prepare: Units

Special requirements:

Save as patient's requirements?

Transfusion Indications Perioperative Anemia Other (Specify)

Is this patient suspected or known to have a hematologic malignancy or congenital immunodeficiency?

Donor source

Date of surgery, if applicable

Liver transplant only - indicate risk level

Comments: [+ Add Comments \(F6\)](#)

Add-on: No specimen type selected

✓ Accept ✗ Cancel



Decision Structure

Intervention

Prepare RBCs for Transfusion (must have Type and Screen available), 1 Units ✓ Accept ✗ Cancel Remove

Priority:

Prepare: Units

Special requirements:

Save as patient's requirements?


Is this patient suspected or known to have a hematologic malignancy or congenital immunodeficiency?

Date of surgery, if applicable

Liver transplant only - indicate risk level

Comments: [+ Add Comments \(F6\)](#)

Last Resulted: Lab Test Results



Transfuse Order

Original

Transfuse RBC ✔ Accept ✖ Cancel

Priority:

Transfuse: Units

Has signed consent been obtained?

Transfusion duration per unit in hours

Comments:

Last Resulted: Lab Test Results

Component	Time Elapsed	Value	Range	Status
Hemoglobin	127 days (12/17/19 0000)	11.1	g/dL	Final result
	127 days (12/17/19 0000)	12.0	g/dL	Final result

✔ Accept ✖ Cancel



Decision Structure



Decision Structure + Information Intervention

Intervention

Transfuse RBC: 1 Units ✔ Accept ✖ Cancel Remove

Priority:

Process Inst.: Units

Transfusion Indications

- Hgb < 8 g/dL AND with known cardiovascular disease WITH symptoms of ischemia
- Hemodynamically unstable with an acute bleed
- Perioperative acute blood loss anemia with expected Hgb nadir < 7 g/dL
- Cytotoxic chemotherapy with expected nadir Hgb < 7g/dL
- Anemia with symptoms that are intolerable without transfusion
- Other (Specify)

Transfusion duration per unit in hours

Transfuse RBC: 1 Units

Accept **Cancel** Remove

Priority: Routine

Process
Inst.:

Transfuse: 1 Units **1 Units**

! Transfusion Indications

If Hgb 6.9 g/dL or less – indications not displayed

Transfusion duration per unit in hours

1 2 3 4 Rapid infuser Maximum rate

Other (please specify)




Decision Structure

Does *overt* clinical-decision support (CDS) change provider behavior?

If so, how should it be displayed?



UCH Provider



Order (Set)
Modify

Order (Set)
Modify

Order(Set)
Modify



Non-Interruptive Conditional Alert




▼ Red Blood Cells

Decision Information

! Potential Patient Harm - Consider Restrictive Transfusion Strategy

Lab Results Last 3 days.

Component	Value	Date/Time
Hemoglobin	7.5 (A)	05/12/2021 2246



The Hemoglobin (Hgb) is greater than 6.9 g/dL which is tolerated by most hospitalized, stable patients. Transfusion above this level may result in harm to your patient.

Limit transfusions to patients:

1. Hgb <7 g/dL
2. Hgb <8 g/dL AND with known cardiovascular disease WITH symptom of ischemia
3. Hemodynamically unstable with an acute bleed
4. Preoperative acute blood loss anemia with expected Hgb nadir < 7 g/dL
5. Cytotoxic chemotherapy with expected nadir Hgb < 7g/dL
6. Anemia with symptoms that are intolerable without transfusion



Decision Assistance

Transfusing 1 Unit at a time is preferred

The prepare order notifies the Blood Bank of the quantity of blood products needed as well as any special requirements. The transfuse order goes to the nursing staff. It provides transfusion instructions, includes hyperlinks that allow the nurse to notify the Blood Bank when the ordered product needs to be released, and launches administration documentation groups in flowsheets.

Interruptive (BPA) Conditional Alert



Decision Information

BestPractice Advisory - Bruce, Stella

Attention (1)

⚠ Potential Patient Harm (#8010)

Consider Restrictive Transfusion Strategy

Hemoglobin	Date	Value	Ref Range	Status
	04/18/2021	7.5 (A)	12.1 - 16.3 g/dL	Corrected

Your patients Hemoglobin (Hgb) is greater than 6.9 g/dL which is well tolerated by most hospitalized, stable patients. Transfusing above this level may result in harm to your patient.

Transfusing 1 unit at a time is preferred

Remove the following orders? _____

Acknowledge Reason _____



Decision Structure




Decision Assistance

Results



UCH Provider




Order (Set) Modify	Order (Set) Modify + In-line CDS	Order(Set) Modify + Interruptive CDS
-------------------------------	--	--



Results



UCH Provider



pre-intervention = 2/1/2019-4/5/2021

post-intervention = 4/6/2021-4/5/2022

NOTE: early COVID pandemic period (3/3/2020 - 8/24/2020) were removed

Characteristic [?]	Overall, N = 10,451 ^{1?}	Group 1, N = 3,254 ^{1?}	Group 2, N = 3,675 ^{1?}	Group 3, N = 3,522 ^{1?}
compliant_type[?]	[?]	[?]	[?]	[?]
compliant [?]	5,239 (50.2%) [?]	1,599 (49.2%) [?]	1,743 (47.5%) [?]	1,897 (53.9%) [?]
non-compliant_hgb [?]	4,682 (44.8%) [?]	1,503 (46.2%) [?]	1,740 (47.4%) [?]	1,439 (40.9%) [?]
non-compliant_units [?]	520 (5.0%) [?]	150 (4.6%) [?]	189 (5.1%) [?]	181 (5.1%) [?]
missing [?]	10 [?]	2 [?]	3 [?]	5 [?]
¹ n (%) [?]				

NO difference between groups



Results

Characteristic [?]	Overall, N = 32,032 ^{1?}	pre, N = 21,580 ^{1?}	post, N = 10,452 ^{1?}
compliant [?]	15,055 (47.0%) [?]	9,816 (45.5%) [?]	5,239 (50.2%) [?]
missing [?]	33 [?]	23 [?]	10 [?]

¹n (%)[?]

[?]

Model results indicate a significant difference ($p < 0.001$) in compliance between the pre period and the post period, after accounting for linear time and provider



Results



Estimated number of units “saved” in one-year

1827





?





BestPractice Advisory - Roo, Koda

Attention (1)



! Hyperlipidemia (BPA # 89568)

Your patient may have hyperlipidemia based on an encounter or problem list diagnosis.

RECOMMENDATION: Consider starting a statin medication.

This is a best practice at our institution.

[Open hyperlipidemia treatment pathway](#)

Dismiss





Decision Information

Provide access to relevant information.

BestPractice Advisory - Roo, Koda

Attention (1)


! Hyperlipidemia (BPA # 89568)

Your patient may have hyperlipidemia based on an encounter or problem list diagnosis.

RECOMMENDATION: Consider starting a statin medication.

This is a best practice at our institution.

[Open hyperlipidemia treatment pathway](#)




Decision Structure?

Dismiss



 **Morning Ride**
22 hours ago by Jille Duffy



Add friends who didn't record or aren't on Strava yet. [Add Friends](#)





15:20
MOVING TIME

3 MI
DISTANCE

11.9 MPH
AVG SPEED

87 FT
ELEVATION GAIN

70
CALORIES

THIS WEEK
0 / 10 mi

M T W T F S S



0h0m | 0 ft

THIS YEAR
5 / 350 mi

TODAY
149 mi behind pace

[Manage Your Goals](#) >





Decision Assistance

Facilitate commitment: Encourage self and/or public commitment



15%

\$2.45

20%


\$3.26

25%

\$4.08

Custom Tip Amount

No Tip



15%

\$2.45

20%


\$3.26

25%

\$4.08

Custom Tip Amount

No Tip



Decision Information

Provide social reference point.



Decision Structure

Chronic Opioid Patients

Data as of: 10/31/2014

Go Back

15
\$

	Total of Current Opioid Patients	Panel Size (12-mon)	% of Panel on Chronic Opioids	Total of 1-Utox Patients (6-mon)	% Utox Completed	Total of Contract Patients (ever)	% of Opioid Contract (ever)	Total of Contract Patients (12-mon)	% of Opioid Contract (12-mon)	Patients Not Seen (Med) within 3-mon	% Not Seen within 3-mon	Patients Seen By BH within 3-mon	% Seen By BH within 3-mon	Facility
Provider 1	7	870	0.80%	7	100.00%	6	85.71%	3	42.86%	0	0.00%	3	42.86%	CHC Site 1
Provider 2	55	1239	4.44%	35	63.64%	49	89.09%	41	74.55%	5	9.09%	2	3.64%	CHC Site 2
Provider 3	53	1182	4.48%	42	79.25%	47	88.68%	36	67.92%	4	7.55%	4	7.55%	CHC Site 3
Provider 4	4	172	2.33%	3	75.00%	4	100.00%	2	50.00%	0	0.00%	0	0.00%	CHC Site 4
Provider 5	65	828	7.85%	33	50.77%	18	27.69%	7	10.77%	5	7.69%	12	18.46%	CHC Site 5
Provider 6	21	811	2.59%	19	90.48%	20	95.24%	16	76.19%	2	9.52%	5	23.81%	CHC Site 6
Provider 7	4	1129	0.35%	4	100.00%	3	75.00%	3	75.00%	0	0.00%	1	25.00%	CHC Site 7
Provider 8	27	1207	2.24%	11	40.74%	18	66.67%	7	25.93%	1	3.70%	5	18.52%	CHC Site 4
Provider 9	76	1046	7.27%	48	63.16%	32	42.11%	8	10.53%	2	2.63%	9	11.84%	CHC Site 8
Provider 10	2	836	0.24%	2	100.00%	2	100.00%	1	50.00%	0	0.00%	1	50.00%	CHC Site 3
Provider 11	1	29	3.45%	1	100.00%	0	0.00%	0	0.00%	0	0.00%	1	100.00%	CHC Site 2
Provider 12	9	1102	0.82%	6	66.67%	6	66.67%	4	44.44%	0	0.00%	2	22.22%	CHC Site 3
Provider 13	18	410	4.39%	15	83.33%	12	66.67%	9	50.00%	0	0.00%	7	38.89%	CHC Site 5
Provider 14	3	191	1.57%	3	100.00%	3	100.00%	1	33.33%	0	0.00%	2	66.67%	CHC Site 5



Information


ial reference point.


Chronic Opioid Patients

Provider 1

	Gender	Race	Last Med Encounter w/ PCP	Next Medical Visit	Last Utox Date	Currently On Opioid (Y/N)	Under Opioid Contract (Y/N)	Last BH Date	Next BH Visit	Last Visited BH Provider	Last Visted BH Site
Patient 1	F	Hispanic	10/xx/2014	10/xx/2014	7/xx/2014	Y	Y	1/xx/2014		BH Provider 1	CHC Site 1
Patient 2	F	White	8/xx/2014		8/xx/2014	Y	N	10/xx/2014		BH Provider 1	CHC Site 1
Patient 3	M	Black or African American	9/xx/2014	10/xx/2014	7/xx/2014	Y	Y				
Patient 4	M	Hispanic	10/xx/2014		10/xx/2014	Y	Y	2/xx/2013		BH Provider 2	CHC Site 2
Patient 5	M	Hispanic	10/xx/2014	10/xx/2014	6/xx/2014	Y	Y	10/xx/2014	11/xx/2014	BH Provider 1	CHC Site 1
Patient 6	F	White	8/xx/2014	10/xx/2014	8/xx/2014	Y	Y	8/xx/2014		BH Provider 1	CHC Site 1
Patient 7	F	Hispanic	10/xx/2014		6/xx/2014	Y	Y	8/xx/2013		BH Provider 3	CHC Site 1

ature





Decision Structure

Changing the salience of certain options.





Breakout #1



15 minutes

Design a Nudge for your problem/project!




Making Human-Centered Solutions with Design Thinking

Sam Porter, MD




// more than seven out of ten adults believe the U.S. health system needs fundamental change or complete rebuilding. //




Stremikis K, Schoen C, Fryer A.K. A call for change: the 2011 Commonwealth Fund Survey of Public Views of the U.S. Health System. Issue brief. April 2011;6:1–23.

What is Design Thinking?




What is Design Thinking?





What is Design Thinking?




Is Design Thinking effective?



Is Design Thinking effective?



Is Design Thinking effective?




TILT



Is Design Thinking effective?




Journey map



Source: Laura Ceccacci, Paige Kennedy, Alex Wan, University of Pennsylvania



Solution workflow



Source: Laura Ceccacci, Paige Kennedy, Alex Wan, University of Pennsylvania




1

DESIGN THE RIGHT THING

2

DESIGN THINGS RIGHT



EMPATHIZE

DEFINE

IDEATE

PROTOTYPE

TEST

INDEX

EMPATHIZE

Build **empathy** for
your audience by
learning their **values**



DEFINE

Unpacking the findings from
empathizing into **needs**
and **insights** to develop a
point of view



IDEATE

Ideation is a process of “**going wide**” in terms of concepts and outcomes to **explore** a wide solution space – both a large quantity and broad diversity of **ideas**



PROTOTYPE

Prototyping is getting projects
out of your head and
into the world




TEST

Testing is how to gather feedback, **refine solutions**, and continue to **learn** about your users.



Empathy Mapping

- Structured archetype of an individual
- Representative of a group of people with common experiences, emotions and needs
- Solving for a persona solves for many individuals
- Empathy maps help generate understanding of personas



NNGROUP.COM NN/g



Point of View

Point of View

Once you've completed your **empathy** interviews, you need to turn all that information into a useable problem statement. The **Point of View** framework helps you articulate an actionable problem statement that is targeted toward specific users. It will be the launching off point of brainstorming sessions to generate solutions.

A **Point of View** helps you anchor your project and design solutions meaningfully.

POV Framework

Describe your user in colorful language, including pertinent details.
Then, circle a surprise / insight that represents the most powerful shift in your own perspective.
Think about what this means for the user, and the design of their experience.

Articulate what would be game-changing for your user, assuming your insight is correct.

We met _____.

We were surprised to notice _____.

We wonder if this means _____.

It would be game-changing to _____.

Ideation, Prototyping, and Testing




1

DESIGN THE RIGHT THING

2

DESIGN THINGS RIGHT






Breakout #2

Define a Problem Using Empathy Mapping!

EMPATHY MAP



20 minutes

Part 1: Full Group (10 min)

Take notes while we interview a provider about their experience prescribing opioids. Note **phrases, thoughts, and feelings** as well as the **things they say they do**.


Part 2: Breakouts (10 min)

Each breakout group will be assigned a different section of the **Empathy Map** to fill out. Then, we'll come together and discuss our insights and put them together into a Point of View.




Why choose design thinking?


It is an applied research and innovation framework that:



**prioritizes
empathy**



**involves
highly diverse and
collaborative
teams**



**encourages action-
oriented rapid
prototyping**



**user-derived insights
rather than top-down
hypotheses**

Roberts JP, Fisher TR, Trowbridge MJ, Bent C. A design thinking framework for healthcare management and innovation. *Healthc (Amst)*. 2016 Mar;4(1):11-4.



Thank You



BREAK-TIME

Come back at ...!



User-centered design

Brad Morse, PhD, MA
brad.morse@cuanschutz.edu


Objectives

- Define User-centered design [UCD]
- Provide rationale for using UCD
- Clarify UCD principles
- Illustrate the UCD process
- Usability testing
- Breakout



Origins

- The term was coined in 1977 by Rob Kling who was working in the domain of software design. The term was popularized by Don Norman who incorporated the idea in his work on improving how people experience the use of items.



Origins

- Good design is possible!
- Make things visible
- Exploit natural relationships that marry function & control
- Use constraints strategically
- GOAL: guide the user to the right action, on the right control, at the right time




Kling, R. (1977). The organizational context of user-centered software designs. MIS quarterly, 41-52.




Definition

- UCD is an iterative design process in which designers focus on the users and their needs in each phase of the design process
- Design teams involve users throughout the design process via a variety of research and design techniques, to create highly usable and accessible products for them




Definition

- Human-centered design is an approach to interactive system development that focuses specifically in making systems usable
- It is a multi-disciplinary activity



How Design Thinking and UCD are related:



- Design thinking utilizes abductive reasoning to identify and solve complex problems that may affect product design or organizational policies, processes, and function.
- User-centered design focuses on fostering deep empathy with the population you are designing for. The goal is to create solutions with users' needs and feedback at the forefront of all design decisions.




Definition: Users/Clients/Designers

Designers are NOT users

- Difference in orientation to the solution

If designers adopt the user identity, they must...

- Acknowledge biases
- Avoid designing for themselves
- Limit allowing their own experiences with proposed solutions to sway opinions



Rational:

A blue 3D rectangular box with a white text center. The box is rendered with a gradient from light blue on the top and left sides to a darker blue on the bottom and right sides, giving it a three-dimensional appearance. The text is centered within the box.

The goal of UCD is to see problems from the perspective of users, and then design delightful solutions



Rational: UCD seeks to answer

- User needs
- Task details: frequency & order
- Context in which happens
- Constraints
- Expectations of functionality
- Output required and its form
- FACILITATE the USERS COGNITIVE PROCESS



UCD Principles

1. User focus
2. Active user involvement
3. Evolutionary systems development
4. Simple design representation
5. Prototyping
6. Evaluate use in context




UCD Principles

7. Explicit and conscious design activities
8. A professional attitude
9. Usability champion
10. Holistic design
11. Processes customization
12. A user-centered attitude




UCD Process



User-centered design



UCD Process: Alternate Process Map



@ohmscorons

Usability testing: Think aloud



Think aloud: Implementation details

Usability testing must be context-rich and accurate. The data you collect should reflect actual world parameters where the work organically happens.

1. Virtual
2. In-person
3. Contextual analysis
4. Data collection forms





Breakout #3




10 minutes

Usability Testing Planning

1. Where does the test take place?
2. What time does the test happen?
3. How will you simulate the real world?
4. What data will you collect?



Pre-Mortem Analysis



Pre-Mortem Analysis

- Comes at the beginning of a project rather than the end
- Unlike a typical problem identification session in which stakeholders are asked what might go wrong, the premortem assumes that the project has been implemented and failed, and asks what did go wrong.






Pre-Mortem Analysis

- quickly engages QI stakeholders
- creates an environment of psychological safety
- way to gather feedback to maximize the effectiveness of implementing planned QI projects
- vs. user-testing -- allows for a more global assessment of potential failures rather than beyond the individual user-level.







Pre-Mortem Analysis



Pre-Mortem Analysis: Brain Writing



- 6** participants
- 3** ideas / participant
- 5** times passing ideas

